Screening Biomarkers for Colorectal Cancer
For average-risk adults, the primary recommended screening biomarkers are fecal immunochemical test (FIT) performed annually or multi-target stool DNA tests (mt-sDNA/mt-sRNA) every 3 years, with colonoscopy every 10 years as the first-tier structural examination option. 1, 2, 3
First-Tier Stool-Based Biomarker Options
The most recent guidelines from 2022-2026 establish a clear hierarchy of screening biomarkers:
Preferred Stool-Based Tests
Annual FIT: Recommended as a first-tier option with strong evidence (moderate-quality) 1, 2
Multi-target stool DNA/RNA tests every 3 years: Strong recommendation despite low-quality evidence 1, 6
Critical Implementation Point
Any positive non-colonoscopy screening test requires timely colonoscopy follow-up, preferably within 6 months, to complete the screening process. 3, 6 This is non-negotiable—a positive FIT with negative recent colonoscopy should generally prompt repeat colonoscopy 4.
Blood-Based Biomarkers: Limited Role
The 2026 ACS guideline update provides important clarification on blood-based tests 6:
- Blood-based cell-free DNA assays are NOT first-line options
- They demonstrate lower sensitivity for advanced precancerous lesions and stage I cancers compared to stool-based tests
- Modeling studies predict less effectiveness in reducing CRC incidence and mortality
- Should only be recommended for patients who decline or do not complete preferred screening tests 6
The evidence shows blood biomarkers (CEA, glucose metabolism markers, liver enzymes) achieve modest improvements in risk prediction (AUC 0.66-0.82) but lack sufficient performance for primary screening 8, 9, 10. The U.S. Multi-Society Task Force specifically recommends against Septin9 for CRC screening 1.
Age-Specific Recommendations
Starting Age
- Begin screening at age 45 years for average-risk adults (qualified recommendation from ACS 2018, reaffirmed 2026) 3, 6
- Age 50 remains a strong recommendation threshold with high-quality evidence 1, 2
- African Americans: consider starting at age 45 (weak recommendation) 1
Stopping Age
- Continue through age 75 years if life expectancy >10 years 1, 3
- Stop screening at age 75 or when life expectancy <10 years for those up-to-date with negative prior tests 1, 2
- Ages 76-85: individualize based on prior screening history and comorbidities 1, 3
- Discourage screening after age 85 1, 3
Emerging Biomarkers Under Investigation
While not yet recommended for routine screening, research is advancing on:
- Methylation biomarkers (SEPT9, BMP3, NDRG4): Sensitivity 70-80% for Epi proColon assay 7
- Circulating tumor DNA (ctDNA): Promising for post-treatment surveillance and recurrence prediction, but not validated for primary screening 11
- Combination panels: Serum protein biomarkers achieving >85% sensitivity/specificity in research settings 5, but lacking population-based validation 9, 12
Common Pitfalls to Avoid
- Do not perform upper GI evaluation for positive FIT with negative colonoscopy in the absence of upper GI symptoms 4
- Do not use colonoscopy as the only screening option offered—multiple options improve participation rates 1, 2
- Do not recommend blood-based tests as first-line screening—reserve for those declining preferred options 6
- Do not continue screening beyond age 75 in patients with negative prior colonoscopy and limited life expectancy 2
Quality Monitoring
Physicians performing FIT screening should monitor quality metrics, and those performing colonoscopy must measure adenoma detection rates 1. This ensures the screening program achieves its mortality reduction goals, which require approximately 10.3 years to prevent one CRC death per 1000 patients screened 1.